http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1043158-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bba842fc4d37dfcaced1b55bc0c91c7c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C63-72 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C63-72 |
| filingDate | 1963-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_555bc4f5dccb415104bb415550a847e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_648f511575a8d8e67b4d136d42d43402 |
| publicationDate | 1966-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1043158-A |
| titleOfInvention | Improvements in or relating to piperidylalkidene-5h-dibenzo(a,d)cycloheptenes |
| abstract | Novel compounds of general formula <FORM:1043158/C2/1> wherein Z is -CH2-CH2 or -CH=CH-. X is a hydrogen, fluorine chlorine or bromine atom, R1 is hydrogen or a (C1-C4) alkyl radical and R2 is hydrogen or alkyl (C1-C4), alkenyl (C2-C4), or C2 or C3 hydroxyalkyl and salts and quaternary compounds thereof are prepared by dehydration with a strong acid or anhydride of a compound of general formula <FORM:1043158/C2/2> and when R2 is hydrogen in the resulting compound further optionally introducing the radical R2 by alkylation, acylation and reduction, or reaction with an epoxide. The compounds of the second general formula above are prepared by reduction of the corresponding quaternary pyridyl compound which is prepared by quaternization of the reaction product of a compound of Formula V <FORM:1043158/C2/3> with a sodium or lithium derivative of a compound of formula <FORM:1043158/C2/4> The ketones of Formula V wherein X is fluorine or bromine are prepared by cyclization of the corresponding o-(p-halogenophenethyl)-benzoic acid which is itself prepared by reduction of the p-halogeno-benzal phthalide. Pharmaceutical compositions in conventional form for enteral, parenteral or topical administration comprise a compound of the first general formula above and a carrier therefor. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8486980-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8242151-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9475805-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7411072-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9947517-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6214816-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004052847-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004052847-A3 |
| priorityDate | 1962-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.